Chronic pain is a complex issue that is never solely biological. In this series we will explore the biopsychosocial view of pain. This includes three different domains of pain interacting at the same time. Pain is…
- biological (e.g., tissue damage, inflammation)
- psychological (e.g., thoughts and emotions affect pain, memories of pain)
- social/sociological (e.g., socioeconomic, gender, ethnicity, isolation)
Each session will include brief talks by specialists on specific topics for management of chronic pain and supporting patients’ self-management of chronic pain. During each session, community physicians will present a clinical case for feedback and recommendations from other participants and subject matter experts.
This participatory group learning will:
- Increase knowledge of up-to-date chronic pain management approaches.
- Improve ability to assess chronic pain and recommend effective treatment interventions.
- Build knowledge and skills regarding emerging evidence-based mind-body practices to enhance patient self-management of chronic pain.
AMA Designation Statement
Project ECHO® designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE Designation Statement
This activity will provide pharmacists up to 1.0 contact hour. UAN JA4008231-9999-23-065-L08-P has been assigned to this knowledge-based program. CE credit information, based on verification of live attendance and completion of the program evaluation, will be provided to NABP within 60 days after the activity completion.
Disclosure Statement
Project ECHO®, in compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, requires that anyone who is able to control the content of an educational activity disclose all relevant financial relationships they have had within the last 24 months with an ineligible company.
None of the planners nor presenters for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.